Wuxi Biologics (Cayman) to Purchase 30% Equity Interest in WuXi Vaccines

Dow JonesAug 30 06:54 ET

Wuxi Bio (02269) plans to acquire the remaining 30% equity of Wuxi Hyde for 0.1085 billion US dollars.

Wuxi Bio (02269) announced that on August 30, 2024, the company intends to acquire Shanghai Hile Bio-Technology through its subsidiary Wuxi Bio.

Zhitong FinanceAug 30 06:51 ET

Express News | WuXi Biologics - Deal for $108.5 Mln

ReutersAug 30 06:46 ET

Express News | Connected Transaction - Acquisition of 30% Equity Interest in Wuxi Vaccines

ReutersAug 30 06:46 ET

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing

PR NewswireAug 30 05:18 ET

Wuxi Bio's innovative bioprocess technology platform, WuXiUITM, has successfully completed its first 2000-liter GMP production scale-up.

Wuxi Bio's super-enhanced batch feeding bioprocess platform, WuXiUI, has successfully completed its first GMP production of 2000 liters of biopharmaceutical solution. Compared to conventional batch feeding processes, the output has increased fourfold. This production scale-up fully utilizes Wuxi Bio's self-developed cell culture medium, MagniCHO, in combination with WuXiUI technology, which significantly reduces the overall production cost of the biopharmaceutical solution. The successful scale-up of WuXiUI from small-scale production to 2000 liters GMP production and the achievement of a series of excellent results fully demonstrate the advanced, mature, and stable nature of this technology platform, which can greatly enhance biopharmaceutical production.

PR NewswireAug 30 05:17 ET